Company
Jiangsu Hengrui Medicine Co. Ltd
Headquarters: Lianyungang, China
Employees: 28,903
Market Cap
CN¥246.80 Billion
CNY as of Jan. 1, 2023
US$35.78 Billion
Jiangsu Hengrui Medicine Co. Ltd Categories
China
languages
Healthcare
languages
Drug Manufacturers—General
China Healthcare
China Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Pfizer
|
$287.63 B |
|
AbbVie
|
$285.80 B |
|
Merck
|
$281.30 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Stocks & Indices
Jiangsu Hengrui Medicine Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600276